# A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

*PRI Rank #15 · Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026/rank-15*

| Field | Value |
| --- | --- |
| Rank | #15 |
| 18m citations | 29 |
| Journal | Annals of Oncology |
| Year | 2024 |
| DOI | 10.1016/j.annonc.2024.04.012 |
| Corresponding authors | Richard D. Baird |
| Institution | Sarah Cannon Research Institute, United States |

**Ranking page:** [Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026](https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026)

**Paper link:** [10.1016/j.annonc.2024.04.012](https://doi.org/10.1016/j.annonc.2024.04.012)

## Topics

Camizestrant · selective estrogen receptor degrader · estrogen receptor-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · phase I trial · dose escalation · dose expansion · SERENA-1 · Estrogen monotherapy · selective estrogen receptor degrader · selective estrogen receptor degrader

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```